Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/013781PEPTIDE EPITOPE VACCINES FOR COVID-19 AND METHOD OF DESIGNING, MAKING AND USING THE SAME
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2021/056355 Applicant UNIVERSITY OF SOUTHERN CALIFORNIA Inventor BOGDAN, Paul
Computer systems and computer implemented methods are presented for designing and making vaccines to pathogens, particular viral pathogens. Vaccine compositions for COVID-19 are also disclosed, as well as method of using the same.
2.WO/2022/014620SARS-CoV-2 VACCINE
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/JP2021/026368 Applicant BIOCOMO INCORPORATION Inventor FUKUMURA Masayuki
A vaccine that comprises, as an active ingredient, a viral vector which comprises a sequence containing any of the following amino acid sequences (a) to (c) and in which an induced neutralizing antibody presents, on the viral particle envelope, a protein inhibiting the binding of SARS-CoV-2 receptor binding domain (RBD) to human angiotensin-converting enzyme 2 (hACE2). (a) An amino acid sequence represented by SEQ ID NO: 1; (b) an amino acid sequence represented by SEQ ID NO: 1 in which one to several amino acids have been deleted, inserted, substituted or added; and (c) an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence represented by SEQ ID NO: 1.
3.WO/2022/013609SARS-COV-2 VACCINE COMPOSITIONS AND METHODS OF PREPARATION AND USE
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2021/000464 Applicant IMMUNOVACCINE TECHNOLOGIES, INC. Inventor STANFORD, Marianne
The present application relates generally to compositions and methods for preventing COVID- 19, and in particular to vaccine compositions comprising at least one epitope on the spike protein of SARS-CoV-2 that can elicit production of antibodies, including neutralizing antibodies and antibodies that inhibit steps of viral infection (e.g., phagocytosis).
4.WO/2022/015124VACCINE COMPOSITION FOR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/KR2021/009290 Applicant GENEONE LIFE SCIENCE, INC. Inventor PARK, Young Keun
The present invention relates to a vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection. The vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection, according to the present invention, comprises spike, ORF3a, or nucleocapsid as an antigen against SARS-CoV-2. The vaccine composition has a significant effect of inducing antibody immune responses and T-cell immune responses by a plurality of co-expressed antigens compared to those comprising one antigen, and thus can be variously used in the field of prevention of severe acute respiratory syndrome coronavirus 2 infection.
5.WO/2022/015198VACCINE AND METHOD OF PROTECTION AGAINST CORONAVIRUS INFECTION
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2021/000278 Applicant ABIDOV, Musa Tazhudinovich Inventor ABIDOV, Musa Tazhudinovich
The invention relates to medicine and biology and is intended for prevention and treatment of coronavirus infections by using phthalhydrazide derivatives, including Tamerit, which have immunomodulatory activity, either alone or in combination with antiviral drugs of various chemical structures. A method for preventing coronavirus infection is provided, characterized in that, in order to increase the clinical and laboratory efficacy achieved by antiviral agents of the azoloazine-based class (Triazavirin®, Mactavirin®), antimalarial agents and interferon products, a drug based on aminophthalhydrazide salt derivatives in the form of dihydrate, monohydrate and anhydrate in any crystalline form, including Tamerit, at a dose of 0.01 to 4000 mg/kg is administered in combination with the aforementioned drugs to a subject in need thereof. Said drug administration regimen (according to pre-clinical study results) demonstrated that Tamerit provides an overall protective effect of up to 100%, which is higher than the protective effect from the use of antiviral agents alone by 30-35%, and shortens the duration of the period of acute illness and the total duration of illness by 1.5-2 weeks.
6.WO/2022/015662CORONAVIRUS IMMUNOGENIC T CELL EPITOPE COMPOSITIONS AND USES THEREOF
WO 20.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/041313 Applicant ALTIMMUNE, INC Inventor GEORGES, Bertrand
Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection in a mammal.
7.WO/2022/011001METHOD FOR ANTIGEN DETECTION FROM DIRECT CLINICAL SAMPLES
WO 13.01.2022
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/US2021/040672 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor RODWELL, Timothy
In one aspect, the disclosure relates to test strips for detecting and/or monitoring the treatment of a disease in a subject. The test strips are inexpensive and disposable and can be used directly with clinical biological samples from patients including, but not limited to, blood, plasma, saliva, and urine. Also disclosed are methods of using the test strips to quantify antigens produced by a virus or microorganism causing an infectious disease. The methods can be conducted at a point of care for a patient and do not require expensive equipment or extensive operator training. The methods are also rapid to complete and can be used to monitor progress in the treatment of a disease This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
8.WO/2022/011332IMMUNOGENIC COMPOSITION FORMING A VACCINE, AND A METHOD FOR ITS MANUFACTURE
WO 13.01.2022
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Appl.No PCT/US2021/041245 Applicant ENGIMATA, INC Inventor MOSHARRAF, Mitra
An immunogenic composition forming a vaccine includes a nanoparticle adjuvant comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a spike protein from a coronavirus.
9.WO/2022/010353METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/NL2021/050435 Applicant LEYDEN LABORATORIES B.V. Inventor GOUDSMIT, Jaap
The disclosure provides methods for identifying coronavirus cross-reacting antibodies. Such antibodies bind to at least part of the S2 ectodomain of the S protein of at least one common human coronavirus selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1 and bind to at least part of the S2 ectodomain of the S protein of at least one highly pathogenic human coronavirus selected from SARS-CoV- 1, MERS-CoV and SARS-CoV-2. Antibodies identified by the methods described herein are particularly useful for treating or preventing coronaviral infections, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.
10.WO/2022/011210TREATMENT FOR SEVERE ACUTE RESPIRATORY ILLNESS ASSOCIATED WITH CORONAVIRUS
WO 13.01.2022
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No PCT/US2021/041004 Applicant DOWNING, Sean Inventor DOWNING, Sean
A method is provided for identifying a patient having a respiratory illness and administering to the patient a combination of an anti-inflammatory agent and a leukotriene inhibitor. The method may include treating respiratory illness associated with a coronavirus, and may it may further include reducing or preventing an inflammatory response or cytokine storm for those patients without impairing their immune response against the underlying pathogen.